Wellington, New Zealand & Cincinnati, Ohio | April 13, 2026
BioOra Limited and Cincinnati Children’s Hospital Medical Center have announced a strategic collaboration to advance Atla-cel (atlacabtagene autoleucel), a third-generation CD19-directed CAR-T cell therapy, into clinical development for children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The initiative builds on promising adult clinical data demonstrating markedly reduced neurotoxicity, addressing one of the most critical safety concerns in pediatric oncology. This collaboration aims to deliver a safer and more effective immunotherapy option for children with limited treatment alternatives, potentially transforming outcomes in one of the most challenging forms of childhood cancer.
Next-Generation CAR-T Design Targets Pediatric Safety Challenges
Atla-cel represents a significant advancement in CAR-T therapy design, incorporating innovations to enhance both anti-tumor activity and tolerability. While earlier CAR-T therapies have shown strong efficacy, their adoption in pediatric populations has been limited by risks such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). These adverse effects are particularly concerning in children due to the vulnerability of the developing brain.
Data from the ENABLE-1 Phase 1 study in adults demonstrated low rates of severe CRS and significantly reduced ICANS, providing a strong rationale for pediatric investigation. This improved safety profile could enable broader use of CAR-T therapy in children and potentially allow for outpatient treatment approaches, reducing the need for prolonged hospital stays and improving patient quality of life.
Global Clinical Program Expands Access to Advanced Therapies
Advertisement
Under the collaboration, Cincinnati Children’s will lead a global clinical trial program, enrolling pediatric patients across the United States, New Zealand, and potentially Australia. The trial will be led by Dr. Stella M. Davies, a leading expert in pediatric hematology-oncology and cellular therapies. This program builds on the ENABLE clinical trial framework, which has already demonstrated encouraging safety and efficacy signals in adult populations.
By combining BioOra’s expertise in cell therapy development and GMP manufacturing with Cincinnati Children’s leadership in clinical research, the partnership is positioned to accelerate the translation of Atla-cel into pediatric clinical use. This global, multi-center approach enhances both data robustness and patient access, critical factors in advancing innovative therapies for rare diseases
Addressing Unmet Needs in Pediatric Leukemia Treatment
Relapsed or refractory B-cell acute lymphoblastic leukemia remains a major clinical challenge, with limited treatment options and poor long-term outcomes for affected children. The development of Atla-cel aims to address these unmet needs by providing a therapy that combines high efficacy with improved safety. The therapy’s design also supports automated and scalable manufacturing processes, enabling broader accessibility and faster delivery to patients. If successful, Atla-cel could represent a new generation of CAR-T therapies specifically optimized for pediatric use, overcoming barriers that have historically limited access to advanced immunotherapies in this population.
Strategic Collaboration Strengthens Cell Therapy Innovation
The partnership highlights the importance of academic-industry collaboration in advancing complex therapies such as CAR-T. By integrating clinical expertise, advanced manufacturing infrastructure, and translational research, BioOra and Cincinnati Children’s aim to accelerate innovation in cell-based cancer therapies. The addition of Cincinnati Children’s leadership to BioOra’s board further strengthens the strategic alignment between the organizations, ensuring a coordinated approach to development and commercialization. This collaboration reflects a broader industry trend toward precision medicine and next-generation immunotherapies, which are reshaping the landscape of cancer treatment.
The collaboration between BioOra and Cincinnati Children’s marks a significant step forward in the development of safer and more effective CAR-T therapies for pediatric leukemia. With strong clinical foundations, innovative design, and a global development strategy, Atla-cel has the potential to redefine treatment standards and improve outcomes for children with relapsed B-ALL. As the clinical program progresses, this partnership underscores the growing role of precision immunotherapy in transforming pediatric oncology and addressing critical unmet medical needs.
Source: BioOra press release
